Testosterone therapy: Treatment of metabolic disturbances in heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 1, 2011, Pages 14-23

  Naghi, Jesse J ^a   Philip, Kiran J ^a   Dilibero, Deanna ^a   Willix, Robert ^b   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cenegenics Research Foundation   (United States)

Author keywords

androgen deficiency; heart failure; hypogonadism; testosterone

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE IRRITATION; ARTICLE; ATHEROSCLEROSIS; CARDIAC PATIENT; CARDIOVASCULAR AUTOREGULATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; ERYTHROPOIESIS; FLUID RETENTION; FUNCTIONAL STATUS; GYNECOMASTIA; HAIR LOSS; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HIRSUTISM; HUMAN; HYPERTENSION; HYPOGONADISM; IMMUNOMODULATION; LOW DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SURVIVAL; TESTOSTERONE BLOOD LEVEL; TREATMENT PLANNING; TREATMENT RESPONSE; VASODILATATION;

DRUG ADMINISTRATION ROUTES; DRUG MONITORING; HEART FAILURE; HEMODYNAMICS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 79951499843     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410378121     Document Type: Article

References (67)

1. Levy D., Kenchaiah S., Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002 ; 347 (18). 1397-1402. (Pubitemid 35239711)
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235.
3. von Haehling S., Doehner W., Anker SD Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007 ; 73 (2). 298-309. (Pubitemid 44937690)
4. von Haehling S., Lainscak M., Springer J., Anker SD Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009 ; 121 (3). 227-252.
5. Pugh PJ, Jones RD, Jones TH, Channer KS Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail. 2002 ; 4 (6). 673-680. (Pubitemid 35403074)
6. Anker SD, Chua TP, Ponikowski P., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997 ; 96 (2). 526-534. (Pubitemid 27329429)
7. Chaggar PS, Malkin CJ, Shaw SM, Williams SG, Channer KS Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther. 2009 ; 27 (3). 187-193.
8. Anker SD, Clark AL, Kemp M., et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997 ; 30 (4). 997-1001. (Pubitemid 27435893)
9. Niebauer J., Pflaum CD, Clark AL, Strasburger CJ, Hooper J., Poole-Wilson PA, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998 ; 32 (2). 393-397. (Pubitemid 28396488)
10. Khan UA, Aslam M., Saeed SA Effect of beta adrenergic antagonist on the production of testosterone by rat's Leydig cells. J Ayub Med Coll Abbottabad. 2004 ; 16 (4). 26-28.
11. Kazi M., Geraci SA, Koch CA Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med. 2007 ; 120 (10). 835-840. (Pubitemid 47451287)
12. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005 ; 26 (6). 833-876. (Pubitemid 41428540)
13. Coats AJ, Clark AL, Piepoli M., Volterrani M., Poole-Wilson PA Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994 ; 72 (2suppl). S36 - S39.
14. Haring R., Volzke H., Steveling A., et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010 ; 31 (12). 1495-1501.
15. Guder G., Frantz S., Bauersachs J., et al. Low circulating androgens and mortality risk in heart failure. Heart. 2010 ; 96 (7). 504-509.
16. Jankowska EA, Biel B., Majda J., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006 ; 114 (17). 1829-1837. (Pubitemid 44673358)
17. Jankowska EA, Jakubaszko J., Cwynar A., et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail. 2009 ; 11 (1). 28-38.
18. Jankowska EA, Filippatos G., Ponikowska B., et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail. 2009 ; 15 (5). 442-450.
19. Lainscak M., Doehner W., Anker SD Metabolic disturbances in chronic heart failure: a case for the "macho" approach with testosterone?!. Eur J Heart Fail. 2007 ; 9 (1). 2-3. (Pubitemid 46074484)
20. Schwarz ER, Kapur V., Bionat S., Rastogi S., Gupta R., Rosanio S. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int J Impot Res. 2008 ; 20 (1). 85-91.
21. Schwarz ER, Rastogi S., Rodriguez JJ, et al. A multidisciplinary approach to assess erectile dysfunction in high-risk cardiovascular patients. Int J Impot Res. 2005 ; 17 (supp1). S37 - S43.
22. Apostolo A., Vignati C., Brusoni D., et al. Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment. J Sex Med. 2009 ; 6 (10). 2795-2805.
23. Rastogi S., Rodriguez JJ, Kapur V., Schwarz ER Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int J Impot Res. 2005 ; 17 (suppl 1). S25 - S36.
24. Schwarz ER, Rastogi S., Kapur V., Sulemanjee N., Rodriguez JJ Erectile dysfunction in heart failure patients. J Am Coll Cardiol. 2006 ; 48 (6). 1111-1119. (Pubitemid 44363150)
25. Kapur V., Schwarz ER The relationship between erectile dysfunction and cardiovascular disease. Part I: pathophysiology and mechanisms. Rev Cardiovasc Med. 2007 ; 8 (4). 214-219.
26. Kapur V., Chien CV, Fuess JE, Schwarz ER The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med. 2008 ; 9 (3). 187-195.
27. Schwarz ER, Rodriguez J. Sex and the heart. Int J Impot Res. 2005 ; 17 (suppl 1). S4 - S6.
28. Friedrich N., Volzke H., Rosskopf D., et al. Reference ranges for serum dehydroepiandrosterone sulfate and testosterone in adult men. J Androl. 2008 ; 29 (6). 610-617.
29. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003 ; 87 (2-3). 179-183. (Pubitemid 36135974)
30. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006 ; 27 (1). 57-64. (Pubitemid 41785933)
31. Aukrust P., Ueland T., Gullestad L., Yndestad A. Testosterone: a novel therapeutic approach in chronic heart failure? J Am Coll Cardiol. 2009 ; 54 (10). 928-929.
32. Bassil N., Alkaade S., Morley JE The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009 ; 5 (3). 427-448.
33. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998 ; 31 (2). 391-398. (Pubitemid 28153460)
34. Malkin CJ, Pugh PJ, Jones RD, Kapoor D., Channer KS, Jones TH The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 ; 89 (7). 3313-3318. (Pubitemid 38951897)
35. Jones RD, Pugh PJ, Jones TH, Channer KS The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action ? Br J Pharmacol. 2003 ; 138 (5). 733-744. (Pubitemid 36390629)
36. Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007 ; 42 (1). 11-15. (Pubitemid 46760450)
37. Scragg JL, Jones RD, Channer KS, Jones TH, Peers C. Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun. 2004 ; 318 (2). 503-506. (Pubitemid 38553808)
38. Malkin CJ, Jones RD, Jones TH, Channer KS Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006 ; 111 (4). 265-274. (Pubitemid 44599873)
39. Pugh PJ, Jones TH, Channer KS Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003 ; 24 (10). 909-915. (Pubitemid 36559984)
40. Webb CM, McNeill JG, Hayward CS, de Zeigler D., Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999 ; 100 (16). 1690-1696. (Pubitemid 29485250)
41. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000 ; 102 (16). 1906-1911.
42. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 ; 90 (8). 871-876. (Pubitemid 39005930)
43. Cornoldi A., Caminiti G., Marazzi G., et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010 ; 142 (1). 50-55.
44. Wang C., Swerdloff RS, Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 ; 85 (8). 2839-2853. (Pubitemid 32269162)
45. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol. 1999 ; 83 (1). 123-125, A9. (Pubitemid 29036661)
46. Caminiti G., Volterrani M., Iellamo F., et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 ; 54 (10). 919-927.
47. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS Testosterone treatment for men with chronic heart failure. Heart. 2004 ; 90 (4). 446-447. (Pubitemid 38406925)
48. Morales FJ, Martinez A., Mendez M., et al. A shuttle walk test for assessment of functional capacity in chronic heart failure. Am Heart J. 1999 ; 138 (2Pt1). 291-298. (Pubitemid 29379680)
49. Morales FJ, Montemayor T., Martinez A. Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure. Int J Cardiol. 2000 ; 76 (2-3). 101-105.
50. Arena R., Myers J., Abella J., et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007 ; 115 (18). 2410-2417. (Pubitemid 46717963)
51. El-Mas MM, Afify EA, Mohy El-Din MM, Omar AG, Sharabi FM Testosterone facilitates the baroreceptor control of reflex bradycardia: role of cardiac sympathetic and parasympathetic components. J Cardiovasc Pharmacol. 2001 ; 38 (5). 754-763. (Pubitemid 32983282)
52. Mortara A., La Rovere MT, Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation. 1997 ; 96 (10). 3450-3458. (Pubitemid 27513419)
53. Wang C., Swerdloff R., Kipnes M., et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004 ; 89 (8). 3821-3829. (Pubitemid 39071479)
54. Sullivan ML, Martinez CM, Gennis P., Gallagher EJ The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998 ; 41 (1). 1-15. (Pubitemid 28385246)
55. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 ; 350 (5). 482-492. (Pubitemid 38133769)
56. Nettleship JE, Jones RD, Channer KS, Jones TH Testosterone and coronary artery disease. Front Horm Res. 2009 ; 37: 91-107.
57. Rosano GM, Sheiban I., Massaro R., et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007 ; 19 (2). 176-182. (Pubitemid 46340835)
58. Zmuda JM, Cauley JA, Kriska A., Glynn NW, Gutai JP, Kuller LH Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997 ; 146 (8). 609-617. (Pubitemid 27454548)
59. English KM, Mandour O., Steeds RP, Diver MJ, Jones TH, Channer KS Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 ; 21 (11). 890-894. (Pubitemid 30307417)
60. Kabakci G., Yildirir A., Can I., Unsal I., Erbas B. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology. 1999 ; 92 (4). 221-225. (Pubitemid 30209733)
61. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A., Pols HA Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 ; 87 (8). 3632-3639. (Pubitemid 34879505)
62. Haring R., Volzke H., Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. 2009 ; 58 (9). 2027-2031.
63. Dorr M., Wallaschofski H., Friedrich N. Association of low total testosterone levels and prevalent carotid plaques: result of the study of health in Pomerania. Eur J Epidemiol. 2009 ; 24 (7). 389-391.
64. Hajjar RR, Kaiser FE, Morley JE Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997 ; 82 (11). 3793-3796. (Pubitemid 27509374)
65. Morales A. Androgen replacement therapy and prostate safety. Eur Urol. 2002 ; 41 (2). 113-120. (Pubitemid 35428875)
66. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008 ; 93 (1). 139-146.
67. Bhasin S., Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 ; 91 (6). 1995-2010. (Pubitemid 43854972)